MedTrace Logo

In Vitro Maturation of Human Eggs

NCT02516462 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-05-15

No results posted yet for this study

Summary

Because a large proportion of the embryo's quality is dependent upon the egg, this investigation focuses on treatment of the oocyte during in vitro maturation (IVM). In typical IVF cycles, the egg is recovered when it is mature and ready to be fertilized. However, at this point the oocyte's quality has been set, and cannot be altered. Therefore, to have an impact on oocyte quality the use of in IVM is critical. Development of a successful IVM protocol for clinical use would not only provide an option for women of advanced maternal age, it would also reduce the cost of IVF due to fewer exogenous gonadotropins used for stimulation, and significantly lessen the risk of ovarian hyper-stimulation.

The objective of this research study is to evaluate a newly developed oocyte maturation media system for human clinical use in assisted reproductive technology (ART).

Conditions

Interventions

DEVICE

IVM media

Media to support the nuclear maturation and cytoplasmic competence of human oocytes in culture.

DRUG

Follicle Stimulating Hormone (FSH)

Low dose FSH is administered to stimulate follicle growth.

Sponsors & Collaborators

  • Fertility Laboratories Of Colorado

    collaborator OTHER

  • National Foundation for Fertility Research

    lead OTHER

Principal Investigators

  • Rebecca L Krisher, PhD · CCRM

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2021-12-31
Completion
2022-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02516462 on ClinicalTrials.gov